Researchers and health care stakeholders must actively pursue more representative clinical trials and make changes that encourage the participation of historically marginalized groups within the research community.
After decades of being underrepresented in biomedical research, women have accounted for more than 50% of participants in clinical trials for FDA-approved new drugs in the past four years.
On Monday, March 29, 2021, join the National Academies of Sciences, Engineering, and Medicine for a virtual event regarding its consensus study report, Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research.
SWHR President & CEO Kathryn G. Schubert and Dr. Margaret McCarthy, professor and chair of the Department of Pharmacology at […]
Although women account for almost two-thirds of those diagnosed with Alzheimer’s disease, researchers have largely neglected to study sex as […]
The Biology of Sex Differences journal welcomed Dr. Jill Becker, PhD, as its new editor-in-chief earlier this month.
SWHR and the Endocrine Society hosted a virtual congressional briefing to discuss the importance of including sex as a biological variable in research.
Pregnant people have historically been excluded from clinical research on the grounds of protecting women and their pregnancies from harm. […]
This speaker series will amplify research relevant to the health of women and support informed decisions about research participation by diverse women.